Results 1 to 10 of about 196,164 (338)

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial

European Respiratory Journal, 2023
Background Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used as rescue therapy.
J. Mankikian, A. Caille, M. Reynaud‐Gaubert, M. Agier, J. Bermudez, P. Bonniaud, Raphaël Borie, P. Brillet, J. Cadranel, I. Court-Fortune, B. Crestani, M. Debray, E. Gomez, A. Gondouin, Sandrine Hirschi-Santelmo, D. Israel‐Biet, S. Jouneau, K. Juvin, J. Léger, M. Kerjouan, C. Marquette, J. Naccache, H. Nunes, L. Plantier, G. Prévôt, S. Quêtant, J. Traclet, V. Valentin, Y. Uzunhan, L. Wémeau-Stervinou, T. Bejan-Angoulvant, V. Cottin, S. Marchand-Adam   +32 more
semanticscholar   +1 more source

RITUXIMAB-INDUCED SEVERE ACUTE THROMBOCYTOPENIA IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA

Hematology, Transfusion and Cell Therapy, 2022
Objective: Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological.
Taha Ulutan Kars, Zahit Furkan Yorgancı, Osman Yaşkıran, Atakan Tekinalp   +3 more
doaj   +1 more source

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood, 2022
Shanafelt et al report on the long-term outcome of the pivotal ECOG-ACRIN E1912 study, detailing the continued superiority of ibrutinib plus rituximab (IR) compared to the prior standard treatment—fludarabine, cyclophosphamide and rituximab (FCR)—for ...
T. Shanafelt, X. V. Wang, C. Hanson, E. Paietta, S. O'Brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina K Singh, M. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman, N. Kay   +21 more
semanticscholar   +1 more source

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab

Frontiers in Immunology, 2020
Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin type-1 domain-containing 7A (THSD7A) in 70 and 3% of patients, respectively.
Sonia Boyer-Suavet, Sonia Boyer-Suavet, Marine Andreani, Maël Lateb, Benjamin Savenkoff, Vesna Brglez, Sylvia Benzaken, Ghislaine Bernard, Patrick H. Nachman, Vincent Esnault, Vincent Esnault, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski   +13 more
doaj   +1 more source

Rituximab resistance [PDF]

Best Practice & Research Clinical Haematology, 2011
Rituximab has become a ubiquitous component of treatment regimens for follicular non-Hodgkin lymphoma. Despite widespread clinical use, the mechanisms by which tumor cells resist rituximab-mediated destruction remain unclear. Rituximab relies in part on immune effector mechanisms for its antitumor effect, and thus resistance may be mediated not only by
Andrew R, Rezvani, David G, Maloney
openaire   +2 more sources

Rituximab (Rituxan) [PDF]

American Journal of Neuroradiology, 2010
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
David T, Selewski, G V, Shah, R J, Mody, P A, Rajdev, S K, Mukherji   +4 more
openaire   +2 more sources

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

JAMA Neurology, 2020
Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk ...
G. Luna, Peter Alping, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, J. Lycke, P. Nilsson, J. Salzer, A. Svenningsson, M. Vrethem, T. Olsson, F. Piehl, T. Frisell   +15 more
semanticscholar   +1 more source

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

JAMA Neurology, 2022
This randomized clinical trial investigates the efficacy and safety of rituximab compared vs placebo as an add-on with standard of care for myasthenia gravis.
F. Piehl, Ann Eriksson-Dufva, Anna Budzianowska, Amalia Feresiadou, William Hansson, M. A. Hietala, I. Håkansson, Rune Johansson, D. Jons, I. Kmezic, C. Lindberg, J. Lindh, F. Lundin, I. Nygren, A. Punga, R. Press, K. Samuelsson, P. Sundström, O. Wickberg, S. Brauner, T. Frisell   +20 more
semanticscholar   +1 more source

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

JCI Insight, 2022
BACKGROUND Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell ...
X. Mariette, F. Barone, C. Baldini, H. Bootsma, K. Clark, S. De Vita, D. Gardner, R. B. Henderson, Michael Herdman, K. Lerang, P. Mistry, R. Punwaney, R. Seror, J. Stone, P. V. van Daele, A. van Maurik, N. Wisniacki, D. Roth, P. Tak   +18 more
semanticscholar   +1 more source

Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts [PDF]

Journal of Nephropathology, 2018
Context: IgA nephropathy (IgAN) as an autoimmune disease is the most common cause of glomerulonephritis worldwide. Rituximab effectively depletes B cells and reduces serum levels of IgA1 antibodies.
Mohammad-Reza Tamadon, Jamileh Moghimi, Hamed Rezaei   +2 more
doaj   +1 more source